Evidence map›Paper›PMID 39994765›Full record

ArticleJournal of neuroinflammation2025

RGS10 attenuates systemic immune dysregulation induced by chronic inflammatory stress.

Janna E Jernigan, Hannah A Staley, Zachary Baty, MacKenzie L Bolen, Beatriz Nuñes Gomes, Jenny Holt, Cassandra L Cole, Noelle K Neighbarger, Kruthika Dheeravath, Andrea R Merchak and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Janna E JerniganCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0000-0003-0771-384X
Hannah A StaleyCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0009-0001-8284-6178
Zachary BatyDepartment of Biomedical Engineering, College of Engineering, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0009-0005-2659-8543
MacKenzie L BolenCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0000-0003-1973-3784
Beatriz Nuñes GomesCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.
Jenny HoltCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.
Cassandra L ColeCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0009-0006-9245-9960
Noelle K NeighbargerCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0009-0007-6649-0988
Kruthika DheeravathCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.
Andrea R MerchakCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0000-0002-0180-6044
Kelly B MeneesCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0000-0003-4282-8546
Stephen A CoombesDepartment of Applied Physiology and Kinesiology, College of Health and Human Performance, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0000-0001-8616-5364
Malú Gámez TanseyCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, USA. mgtansey@ufl.edu.ORCID https://orcid.org/0000-0002-1719-4708

Funding

Interdisciplinary Training in Movement Disorders and NeurorestorationT32NS082168 · NINDS · UNIVERSITY OF FLORIDA · PI Melissa Jo Armstrong, David E Vaillancourt · 2015 to 2026
$2.8M
National Institute of Health and the National Institute of Neurological Disorders and Stroke Grant RF1NS28800NINDS NIH HHS T32 NS082168NINDS T32 Pre-Doctoral Training Program in Movement Disorders and Neurorestoration 5T32NS082168-09The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Aligning Science Across Parkinson's (ASAP) initiative ASAP-020527
6 · The paper itself

Abstract

Regulator of G-protein signaling 10 (RGS10), a key homeostatic regulator of immune cells, has been implicated in multiple diseases associated with aging and chronic inflammation including Parkinson's Disease (PD). Interestingly, subjects with idiopathic PD display reduced levels of RGS10 in subsets of peripheral immune cells. Additionally, individuals with PD have been shown to have increased activated peripheral immune cells in cerebrospinal fluid (CSF) compared to age-matched healthy controls. However, it is unknown whether peripheral immune cells in the CSF of individuals with PD also exhibit decreased levels of RGS10. Utilizing the Michael J. Fox Foundation Parkinson's Progression Markers Initiative (PPMI) study we found that RGS10 levels are decreased in the CSF of individuals with PD compared to healthy controls and prodromal individuals. As RGS10 levels are decreased in the CSF and circulating peripheral immune cells of individuals with PD, we hypothesized that RGS10 regulates peripheral immune cell responses to chronic systemic inflammation (CSI) prior to the onset of neurodegeneration. To test this, we induced CSI for 6 weeks in C57BL6/J mice and RGS10 KO mice to assess circulating and CNS-associated immune cell responses. We found that RGS10 deficiency synergizes with CSI to induce a bias for inflammatory and cytotoxic cell populations, a reduction in antigen presentation machinery in peripheral blood immune cells, as well as in and around the brain that is most notable in males. These results highlight RGS10 as an important regulator of the systemic immune response to CSI and implicate RGS10 as a potential contributor to the development of immune dysregulation in PD.

Indexed as

InflammationParkinson DiseaseRGS ProteinsAgedAnimalsFemaleHumansMaleMiceMice, Inbred C57BLMice, KnockoutMiddle AgedRGS10 protein, humanRgs10 protein, mouseRGS ProteinsChronic systemic inflammationImmune dysregulationNeurodegenerative diseasesNeuroinflammationParkinson’s diseaseRegulator of G protein signaling 10 (RGS10)

Identifiers

PMID39994765
PMCPMC11852585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.